Selective N-Hydroxyhydantoin Carbamate Inhibitors of Mammalian Serine Hydrolases  by Cognetta, Armand B. et al.
Article
Selective N-Hydroxyhydantoin Carbamate Inhibitors
of Mammalian Serine HydrolasesGraphical AbstractHighlightsd N-Hydroxyhydantoin carbamates inhibit diverse serine
hydrolases
d Inhibitors were discovered for palmitoyl protein thioesterase
1 (PPT1)
d PPT1 inhibitors can be converted into tailored activity-based
probes
d PPT1 inhibitors are active in vivoCognetta et al., 2015, Chemistry & Biology 22, 928–937
July 23, 2015 ª2015 Elsevier Ltd All rights reserved
http://dx.doi.org/10.1016/j.chembiol.2015.05.018Authors
Armand B. Cognetta III, Micah J.
Niphakis, Hyeon-Cheol Lee, Michael L.
Martini, Jonathan J. Hulce, Benjamin F.
Cravatt
Correspondence
cravatt@scripps.edu (B.F.C.),
jhulce@scripps.edu (J.J.H.)
In Brief
Serine hydrolases are a large and diverse
enzyme family. Cognetta et al.
characterize N-hydroxyhydantoin (NHH)
carbamates as a versatile class of serine
hydrolase inhibitors. Activity-based
protein profiling identified selective and
in vivo-active NHH carbamate inhibitors
for multiple serine hydrolases, including
palmitoyl protein thioesterase 1.
Chemistry & Biology
ArticleSelective N-Hydroxyhydantoin Carbamate Inhibitors
of Mammalian Serine Hydrolases
Armand B. Cognetta III,1 Micah J. Niphakis,1 Hyeon-Cheol Lee,1 Michael L. Martini,1 Jonathan J. Hulce,1,*
and Benjamin F. Cravatt1,*
1Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
*Correspondence: cravatt@scripps.edu (B.F.C.), jhulce@scripps.edu (J.J.H.)
http://dx.doi.org/10.1016/j.chembiol.2015.05.018SUMMARY
Serine hydrolase inhibitors, which facilitate enzyme
function assignment and are used to treat a range
of human disorders, often act by an irreversible
mechanism that involves covalent modification of
the serine hydrolase catalytic nucleophile. The
portion of mammalian serine hydrolases for which
selective inhibitors have been developed, however,
remains small. Here, we show that N-hydroxyhydan-
toin (NHH) carbamates are a versatile class of irre-
versible serine hydrolase inhibitors that can be
modified on both the staying (carbamylating) and
leaving (NHH) groups to optimize potency and selec-
tivity. Synthesis of a small library of NHH carbamates
and screening by competitive activity-based protein
profiling furnished selective, in vivo-active inhibitors
and tailored activity-based probes for multiple
mammalian serine hydrolases, including palmitoyl
protein thioesterase 1, mutations of which cause
the human disease infantile neuronal ceroid lipofus-
cinosis.
INTRODUCTION
Serine hydrolases (SHs) represent one of the largest and most
diverse enzyme classes in nature, and perform myriad biochem-
ical functions in physiology and disease (Long and Cravatt,
2011). SHs use a conserved mechanism involving a base-acti-
vated serine nucleophile to hydrolyze amide, ester, and thioester
bonds in biomolecules; however, these enzymes also display
markedly different structures and folds, distribute across virtually
all subcellular compartments in the cell, and accept an expan-
sive array of small- and macro-molecule substrates. In accor-
dance with their diverse biological activities, SHs are targeted
by drugs that are used to treat a wide range of diseases,
including cognitive dementia (Racchi et al., 2004), obesity
(Nelson and Miles, 2005), diabetes (Thornberry and Weber,
2007), and bacterial (Staub and Sieber, 2008) and viral (Marks
and Jacobson, 2012) infections.
Many structurally diverse SH inhibitors have been developed,
which include compounds with reversible and irreversible mech-
anisms of action (Bachovchin and Cravatt, 2012). Irreversible in-
hibitors are largely electrophilic compounds that covalently928 Chemistry & Biology 22, 928–937, July 23, 2015 ª2015 Elsevier Lmodify the conserved catalytic serine nucleophile of SHs. Acti-
vated carbamates, for instance, irreversibly carbamylate the cat-
alytic serine of SHs, and, in select cases, have been advanced to
furnish selective and in vivo-active inhibitors and drugs for indi-
vidual SHs (Bachovchin and Cravatt, 2012). Carbamate inhibi-
tors can be operationally deconstructed into two primary
elements: the staying group (SG), which remains covalently
bound to the SH catalytic serine, and the leaving group (LG),
which is displaced by the enzyme’s serine nucleophile. Even
though the LG does not ultimately remain part of the covalent
enzyme-inhibitor adduct, it still has substantial influence over
both inhibitor recognition and reactivity due to its structure and
electrophilic character, respectively. As new subtypes of carba-
mate inhibitors have been discovered, differences in the LG are
often found to make large contributions to potency and selec-
tivity (Chang et al., 2011, 2012). Nonetheless, many of the
most effective LGs, such as the p-NO2-phenoxy (Long et al.,
2009), hexafluoroisopropyloxy (Chang et al., 2012), and N-hy-
droxysuccinimide (NHS) (Chang et al., 2013) structures, are
limited in their potential for structural diversification.
We hypothesized that efforts to expand the number of SHs tar-
geted by selective inhibitors would benefit from carbamates that
are more amenable to LG structural diversification. Indeed, in as
much as the substrate selectivity of enzymes is predictive of fea-
tures important for inhibitor binding, it is noteworthy that the
catalytic efficiencies of SHs can be strongly influenced by the
LG structures of substrates (Gross, 1983; Jenkins et al., 2004;
Navia-Paldanius et al., 2012; Saghatelian et al., 2004). Here,
we describe a class of N-hydroxyhydantoin (NHH) carbamates
that incorporate the tempered electrophilicity of NHS carba-
mates, but provide greater synthetic access to diverse and
extended LG structures. We identify lead and optimized NHH
carbamate inhibitors for several SHs using competitive activity-
based protein profiling (ABPP) methods (Niphakis and Cravatt,
2014), including enzymes that heretofore have lacked selective
chemical probes. Prominent among these enzymes was palmi-
toyl protein thioesterase 1 (PPT1) (Bellizzi et al., 2000), mutations
of which cause the human disease infantile neuronal ceroid lipo-
fuscinosis (INCL, or infantile Batten’s disease) (Kyttala et al.,
2006). We show that PPT1, despite being inert toward traditional
broad-spectrum SH activity-based probes containing fluoro-
phosphonate (FP) electrophiles (Wang et al., 2013), reacts
efficiently with NHH carbamates. We further describe NHH car-
bamates that act as selective and in vivo-active inhibitors, aswell
as tailored activity-based probes, for PPT1, thus providing
valuable chemical probes to characterize the function of this
enzyme.td All rights reserved
Figure 1. Synthesis and Initial Characterization of NHH Carbamates as Inhibitors of SHs
(A) Representative classes of carbamate inhibitors of SHs, with variable leaving groups in red and potential sites for structural elaboration in blue. NHS car-
bamates (middle) were prioritized for further exploration over hexafluoroisopropyl (top) or O-aryl (bottom) carbamates due to the synthetic tractability and
structural diversification afforded by their elaboration (right).
(B) Structures of representative NHH carbamates tested for SH inhibition by gel-based competitive ABPP and their in vitro inhibition profiles in a mouse brain
membrane proteome. Brain proteome was pre-treated with NHH carbamates (20 mM, 30 min, 37C) followed by reaction with FP-Rh (1 mM, 30 min, room
temperature) and analysis by SDS-PAGE and in-gel fluorescence scanning.
(C) Concentration-dependent competitive gel-based ABPP (left) and ABPP-SILAC (right) analyses of JJH221 (4). Gel-based ABPP corresponds to mouse brain
membrane proteome. For the ABPP-SILAC analysis, heavy- and light-isotopically labeled PC3 cells were treated with JJH221 (20 mM, 4 hr) or DMSO,
respectively, prior to processing for ABPP-SILAC. SHs showing SILAC ratios (JJH221/DMSO) of less than 0.33 were considered targets of JJH221. Data
represent average values ± SD for two independent experiments.
(D) Concentration-dependent inhibition of mouse brain membrane SHs by representative NHH carbamates as measured by gel-based competitive ABPP. SH
targets of the tested NHH carbamates are marked on the right side of the gel. Assignment of SH enzyme activities in competitive ABPP gels are based on gel
migration patterns consistent with past studies (e.g., Blankman et al., 2007; Hoover et al., 2008).RESULTS
SH Inhibition by NHH Carbamates
In considering ways to increase the structural diversity of estab-
lished chemotypes for serine hydrolase inhibition, we turned our
attention to NHS carbamates, a compound class that has fur-
nished selective and in vivo-active inhibitors of monoacylglycerol
lipase (MAGL, or MGLL) (Niphakis et al., 2013), as well as lead in-
hibitors for additional SHs, while showing minimal cross-reac-
tivity with other proteins in the proteome (Chang et al., 2013).
In principle, the NHS LG provides a good scaffold for structural
elaboration, especially when compared with other established
types of carbamate SH inhibitors that possess, for instance,
p-NO2-phenoxy and hexafluoroisopropyloxy LGs (Figure 1A).
Synthetic derivatization of the NHS group is not, however,
straightforward, and we therefore wondered whether the struc-
turally related NHH, which was expected to exhibit similar LGChemistry & Biology 22,potential while being more amenable to synthetic modification
(Figure 1A), could serve as the basis for creating carbamates
with broad SH inhibition potential.
We synthesized a small library of NHH carbamates and
screened these compounds for inhibitory activity against mouse
brain membrane SHs by competitive ABPP using the SH-
directed probe fluorophosphonate-rhodamine (FP-Rh) (Patricelli
et al., 2001) (Figure 1B). Most of the NHH carbamates showed
activity against one or more brain SHs, some of which could
be assigned based on previous studies (Blankman et al., 2007;
Hoover et al., 2008) (Figure 1B). NHH carbamates with relatively
small extensions to the LG (e.g., the isopropyl and fused methyl
piperazine found in MJN193 and MJN200, respectively) showed
restricted reactivity in mouse brain membranes, with notable
potency and selectivity for ABHD6. In contrast, compounds
with more elaborated LGs (JJH221, JJH248, JJH250, JJH254,
JJH251, ABC5, ABC47; compounds 4–10, respectively) showed928–937, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 929
broader reactivity with brain SHs, suggesting that distal modifi-
cations to the LG substantially influenced these NHH carba-
mate-SH interactions (Figure 1B).
We selected one of the more promiscuous compounds,
JJH221 (4), for analysis by mass spectrometry (MS)-based
ABPPmethods to assess the range of SHs targeted by NHH car-
bamates. JJH221-sensitive SHs were identified using the quan-
titative MS method ABPP-SILAC (stable isotope labeling by
amino acids in cell culture; Mann, 2006) (Adibekian et al.,
2011). In brief, proteomes from isotopically heavy- and light-
amino acid-labeled human PC3 cells were treated with JJH221
(20 mM) or DMSO, respectively, for 4 hr followed by the bio-
tinylated FP probe FP-biotin (Liu et al., 1999) (2.5 mM, 1 hr).
FP-labeled proteomes were then combined and processed for
liquid chromatography-tandem MS (LC-MS/MS) analysis as
described previously (Adibekian et al., 2011). JJH221 (4) was
found to inhibit several human SHs (defined as proteins showing
a 3-fold or greater decrease in signal in the JJH221-treated pro-
teome), including enzymes previously shown to be sensitive to
NHS carbamates (e.g., ABHD6, MGLL) and others for which se-
lective inhibitors are lacking (e.g., ABHD4, ABHD12, PLA2G15,
PNPLA4) (Figure 1C).
We next selected a subset of NHH carbamates with diverse
target profiles in the mouse brain membrane proteome for con-
centration-dependent profiling, which identified compounds
with good potency and selectivity for ABHD6 (MJN193; 1) and
LYPLA1/2 (JJH254; 7), as well as promising lead inhibitors for
ABHD3 and ABHD4 (ABC34 [13] and ABC47 [10]) (Figures 1D
and S1). Various structural classes of ABHD6 (Hsu et al., 2013;
Janssen et al., 2014; Li et al., 2007; Marrs et al., 2011) and
LYPLA1/2 (Adibekian et al., 2012; Biel et al., 2006; Dekker
et al., 2010) inhibitors have been described, and a probe report
has been generated for JJH254 (7) as part of the NIH Molecular
Libraries Program Network (Hulce et al., 2014). We therefore
focused our attention on the lead inhibitors for ABHD3 and
ABHD4.
Optimization of NHH Carbamate Inhibitors for ABHD3
and ABHD4
ABHD3 and ABHD4 hydrolyze distinct classes of phospho-
lipids—medium-chain (Long et al., 2011) and N-acyl (Lee et al.,
2015; Simon and Cravatt, 2006) phospholipids, respectively—
and selective and cell-active inhibitors are lacking for these en-
zymes. ABHD3 and ABHD4 were recombinantly expressed by
transient transfection in HEK293T cells, and the cell lysates com-
bined to provide a convenient assay for monitoring inhibition of
both enzymes by gel-based ABPP (Figure 2A). A focused library
of ABC47 (10) analogs was synthesized, where each compound
retained the basic tertiary amine substituent on the NHH LG and
was diversified off of this amine or on the SG of the carbamate
(Figure 2B). Gel-based ABPP confirmed that ABC47 (10) acts
as a potent dual inhibitor of ABHD3 and ABHD4 (median inhibi-
tory concentration [IC50] valuesof 0.13 and0.03mM, respectively)
and identified additional compounds that preferentially inhibited
ABHD4 over ABHD3 (e.g., ABC34 [13], ABC23 [12], and JJH251
[8]) (Figures 2C and S2). Among the ABHD4-preferring inhibitors,
JJH251 was deprioritized because we had already found that it
inhibited additional SHs such as FAAH and LYPLA1/2 in the
mouse brain membrane proteome (Figure 1B).930 Chemistry & Biology 22, 928–937, July 23, 2015 ª2015 Elsevier LWe next assessed the activity and selectivity of dual
ABHD3/4 and ABHD4-preferring inhibitors in PC3 cells by
ABPP-SILAC. Isotopically heavy and light PC3 cells were
treated in situ with inhibitor (ABC34 [13] [1 mM] or ABC47 [10]
[0.5 mM]) or DMSO for 4 hr and then lysed and processed for
ABPP-SILAC analysis. ABC47 (10) was found to inhibit both
ABHD3 and ABHD4 in PC3 cells with good selectivity (Fig-
ure 2D). Among the 44 SHs detected in this study, only four
additional targets were observed for ABC47: LIPE, PLA2G7,
ABHD6, and CES2 (Figure 2D). ABC34 (13) completely inhibited
ABHD4 and shared a similar off-target profile with ABC47 (10).
Surprisingly, however, partial inhibition (80%) of ABHD3 was
also observed, which indicates that the selectivity window
for ABHD4 over ABHD3 may be compressed in living cells
compared with cell lysates.
These results demonstrate that NHH carbamates can inhibit
both ABHD3 and ABHD4 with good potency and selectivity in
human cells.
Identification of PPT1 as a Target of NHH Carbamates
Designating ABC34 (13) as a promising lead ABHD4 inhibitor, we
next generated an alkyne-derivatized analog of this compound
for direct detection and identification of covalent protein targets
by conjugation to azide reporter tags (Speers and Cravatt, 2004)
using copper-catalyzed azide-alkyne cycloaddition (CuAAC or
click) chemistry (Rostovtsev et al., 2002). We found it most syn-
thetically feasible to replace the methoxy group of ABC34 (13)
with a propargyloxy substituent to yield the ‘‘click’’ probe
ABC45 (probe 1) (Figure 3A). ABC45 inhibited ABHD4, but not
ABHD3, in transfected HEK293T cell proteome in a concentra-
tion-dependent manner as detected by competitive ABPP with
FP-Rh (Figure 3A), and the ABC45-ABHD4 adduct could, in a
complementary manner, be directly visualized by CuAAC conju-
gation to a rhodamine-azide (Rh-N3) tag (Figure 3A). ABC45 also
identified an ABC34-sensitive protein in mouse brain that
matches the expected molecular mass (40 kDa) of ABHD4
andwas absent in brain tissue fromABHD4/mice (Figure S3A).
These data indicate that ABC45 acts as a tailored activity-based
probe for the convenient gel-based detection of ABHD4 in com-
plex biological systems.
We next asked whether ABC45 could be used as a probe in
competitive ABPP-SILAC experiments to identify targets of
ABC34 (13). Isotopically heavy- and light-labeled PC3 cells
were treated with ABC34 (13) (1 mM) or DMSO for 4 hr, respec-
tively, lysed, and then treated with ABC45 (5 mM, 1 hr). The heavy
and light proteomic samples were then conjugated to an azide-
biotin tag by CuAAC, combined and analyzed by LC-MS/MS,
which identified a small subset of SHs, including ABHD4, that
were inhibited by ABC34 (13) (Figure 3B and Table S1). Among
the handful of additional SH targets of ABC34 were ABHD6
and PLA2G7, which were expected based on our ABPP-SILAC
studies with FP-biotin (see Figure 2D), and PPT1, which was in-
hibited by more than 90%. As we and others have reported pre-
viously, PPT1 shows poor reactivity with broad-spectrum FP
probes (Martin et al., 2012; Wang et al., 2013). Accordingly,
PPT1 was not detected in our previous ABPP-SILAC studies
with FP-biotin (Figure 2D). We confirmed the selective enrich-
ment of PPT1 by ABC45 by performing a probe-versus-probe
ABPP-SILAC study, whereby heavy and light PC3 proteomestd All rights reserved
Figure 2. NHH Carbamate Inhibitors of ABHD3 and ABHD4
(A) Recombinant expression of mouse ABHD3 and human ABHD4 by transient transfection in HEK293T cells and detection of both enzymes in a combined lysate
of transfected cells by gel-based ABPP with the FP-Rh probe.
(B) NHH carbamates screened against recombinant ABHD3 and ABHD4.
(C) Concentration-dependent inhibition of ABHD3 and ABHD4 by NHH carbamates using gel-based competitive ABPP. See Figure S2 for curves used to
generate the reported IC50 values. Data represent average values and 95% confidence limits (CI) for three independent experiments.
(D) ABPP-SILAC analysis using FP-biotin as a probe to enrich SHs, showing overlaid in situ SH inhibition profiles for ABC47 (10) (500 nM, 4 hr) and ABC34 (13)
(1 mM, 4 hr) in PC3 cells. Data represent average values ± SD for two independent experiments.were treated with FP-biotin (2.5 mM, 1 hr) and ABC45 (5 mM, 1 hr),
respectively. PPT1, along with two additional SHs, LIPA and
DDHD2, were preferentially enriched by ABC45 over FP-biotin,
while most of the other SHs were more strongly enriched by
FP-biotin (Figure 3C and Table S1). A handful of SHs, corre-
sponding mostly to enzymes that were identified in our ABPP-
SILAC studies as targets of ABC34 (13) (Figures 2D and 3B),
were equivalently enriched by ABC45 and FP-biotin (Figure 3C).
The selective enrichment of PPT1 by ABC45 and the near-
complete blockade of this enrichment by ABC34 (13) suggested
that this enzyme was covalently modified and inhibited by NHH
carbamates. We further explored this possibility by treating
HEK293T cells transfected with human PPT1 (hPPT1) with
ABC34 (13) (5 mM, 4 hr pre-treatment) or DMSO followed by
cell lysis and treatment with ABC45 (5 mM, 1 hr). A strong, but
diffuse ABC34-sensitive, ABC45-labeled protein band was de-
tected by gel-based ABPP in hPPT1-transfected, but not
mock-transfected cell lysates (Figure 3D), and this diffuse signal
was compressed to a tight, faster-migrating band matching the
predicted molecular weight of PPT1 following treatment with
the glycosidase PNGaseF (Figure 3D). Western blotting with an
anti-PPT1 antibody confirmed a similar migration pattern forChemistry & Biology 22,hPPT1 protein in transfected cell lysates (Figure 3D, bottom).
These data indicate that both ABC34 (13) and ABC45 react
with PPT1 and are consistent with previous studies demon-
strating that this enzyme is glycosylated (Camp et al., 1994;
Lyly et al., 2007). In contrast, FP-Rh failed to detect hPPT1 in
transfected cell lysates (Figure 3D).
We next aimed to confirmwhether NHH carbamates react with
the catalytic serine of PPT1, S115 (Bellizzi et al., 2000). HEK293T
cells were transfected with wild-type and an S115A mutant of
PPT1, lysed, and treated with ABC45 followed by CuAAC conju-
gation to an Rh-N3 tag, PNGaseF treatment, and analysis by
SDS-PAGE. This study revealed strong labeling of wild-type
PPT1 but not the S115A mutant (Figure 3E). We also identified
S115 as the site of ABC45 labeling on PPT1 using a quantitative
MS method termed isoTOP-ABPP (Weerapana et al., 2010). In
brief, PPT1-transfected cell lysates were treated with DMSO or
the ABC45 probe (5 mM) for 1 hr and then incubated with
isotopically heavy or light biotin-N3 tags, respectively, under
CuAAC reaction conditions. Each biotin-N3 tag also contained
an intervening TEV protease cleavage site (Weerapana et al.,
2010). Heavy and light probe-labeled proteins were then
combined, enriched by streptavidin chromatography, digested928–937, July 23, 2015 ª2015 Elsevier Ltd All rights reserved 931
Figure 3. Discovery of PPT1 as a Target of NHH Carbamates
(A) Structure of the click probe ABC45 and its reactivity with recombinant ABHD4 in transfected cell lysates. Left side of gel shows a competitive ABPP gel of
ABHD3/ABHD4-transfected cell lysates treated with the indicated concentrations of ABC45 (30 min, 37C) followed by FP-Rh. Right side of gel shows direct
labeling of ABHD4 and other SHs by ABC45 as measured by CuAAC to an Rh-N3 tag.
(B) ABPP-SILAC analysis showing the in situ SH inhibition profile for ABC34 (13) (1 mM, 4 hr) in PC3 cells, where SH enrichment and inhibition were measured with
the ABC45 probe. Data represent average values ± SD for two independent experiments.
(C) ABPP-SILAC analysis comparing the reactivity and enrichment of SHs with FP-biotin (2.5 mM, 1 hr) versus ABC45 (5 mM, 1 hr) in PC3 cell proteomes. Data
represent average values ± SD for two independent experiments.
(D) Verification that recombinant human PPT1 expressed by transient transfection in HEK293T cells reacts with ABC45 (1 mM), but not FP-Rh (1 mM), and the
ABC45 reactivity is blocked by ABC34 (5 mM, 4 hr). PNGaseF treatment causes a shift in PPT1 signals by SDS-PAGE, consistent with the reported glycosylation
state of this protein (Camp et al., 1994; Lyly et al., 2007). Upper, ABPP gel; lower, anti-PPT1 western blot.
(E) ABC45 labels recombinant wild-type PPT1, but not the catalytic serinemutant (S115A) of this enzyme. All sampleswere treatedwith PNGaseF prior to analysis
by gel-based ABPP.
(F) ABC45 labels the catalytic serine S115 of recombinant PPT1 as determined by isoTOP-ABPP analysis of PPT1-transfected cell lysates. Asterisk in the ABC45-
modified tryptic peptide corresponds to the predicted site of ABC45modification (S115) as determined by tandemMS analysis. Asterisk located on theMS1 peak
for the ABC45-modified tryptic peptide marks the time point of MS2 acquisition.sequentially on-bead with trypsin (to remove non-probe-modi-
fied peptides) and TEV to release ABC45-modified peptide(s),
which were analyzed by LC-MS/MS on an LTQ-Orbitrap
instrument. A single ABC45-modified peptide, corresponding932 Chemistry & Biology 22, 928–937, July 23, 2015 ª2015 Elsevier Lto amino acids 105–122, was detected in the isotopically light,
but not heavy samples, and tandem MS analysis assigned the
ABC45 modification site to S115 (Figures 3F, S3B, and S3C).
Taken together, these data indicate that NHH carbamates reacttd All rights reserved
Figure 4. Discovery of Cell-Active NHH
Carbamate Inhibitors of PPT1 and ABHD4
(A) Screening of a subset of NHH carbamates in
hPPT1-transfected HEK293T cells in situ, where
PPT1 inhibition was measured by competitive
ABPP using the ABC45 probe. Structures of the
tested compounds are shown below the ABPP gel.
(B) hPPT1-transfected cell lysates show much
greater hydrolytic activity with the MU-6S-Palm-
bD-Glc substrate compared with mock-trans-
fected cell lysates or hPPT1-transfected cell
lysates pre-treated with ABC44 (17) (50 mM,
30 min). Data represent average values ± SE for
three independent experiments.
(C) Concentration-dependent inhibition of MU-6S-
Palm-bD-Glc hydrolytic activity of hPPT1-trans-
fected cell lysates by ABC44 (17), ABC51 (14), and
JJH254 (7). Data represent average values ± SE for
three independent experiments.
(D) PC3 cells treated in situ with ABC44, but not
ABC51 (500 nM inhibitor; 4 hr) showed substantial
reductions in 4-MU-6S-Palm-bD-Glc hydrolysis
activity compared with DMSO-treated control
cells. Data represent average values ± SE for three
independent experiments.
(E) ABPP-SILAC analysis showing overlaid in situ
SH inhibition profiles for ABC44 (0.1 mM, 4 hr) and
ABC51 (1 mM, 4 hr) in PC3 cells where SH enrich-
ment and inhibition were measured with the FP-
biotin (left) or ABC45 (right) probes. Data represent
average values ± SD for two independent experi-
ments.with PPT1 through carbamylation of the conserved serine nucle-
ophile of the enzyme.
Selective, Cell-Active NHH Carbamate Inhibitors for
ABHD4 and PPT1
Excited that our analysis of NHH targets led to the serendipitous
discovery of a lead inhibitor and tailored activity-based probe for
PPT1,wesought tomoredeeply investigate the structure-activity
relationship (SAR) of the NHH carbamate class in the hopes of
identifying selective inhibitors for both PPT1 andABHD4.We first
assayed a structurally diverse panel of NHH carbamates at 2 or
0.2 mM for in situ inhibition of hPPT1 in transfectedHEK293T cellsChemistry & Biology 22, 928–937, July 23, 2015(Figure 4A). While many compounds ex-
hibited inhibitory activity toward PPT1 at
2 mM, only ABC44 (17) showed substantial
inhibition of hPPT1 at 200 nM (Figure 4A).
ABC44 (17) displayed an in situ IC50 value
for inhibiting recombinant PPT1 of 0.1 mM
as measured by gel-based competitive
ABPP (Table 1 and Figure S4A).
We next tested whether ABC44 in-
hibited PPT1 activity using a substrate
assay. Endogenous substrates for PPT1
remain poorly characterized, but this
enzyme can be assayed with a fluoro-
genic substrate 4-methylumbelliferyl-6-
thio-palmitate-bD-glucopyranoside (MU-
6S-Palm-bD-Glc) (van Diggelen et al.,1999). In this assay, PPT1 hydrolyzes the palmitoyl thioester
bond of the substrate, and exogenous sweet almond b-glucosi-
dase deglycosylates and frees the fluorophore, 4-methylumbel-
liferone (4-MU), which can be measured to assess PPT1 activity.
PPT1-transfected cells displayed a strong increase in MU-6S-
Palm-bD-Glc hydrolysis compared with mock-transfected cells
(Figure 4B), and treatment of these transfected lysates at pH
5.0 with ABC44 (17) fully blocked PPT1 activity with an IC50 value
of 6.5 mM (Figure 4C and Table 1). In addition, in situ treatment
of PC3 cells with ABC44 (17) (500 nM, 4 hr) showed a 90% reduc-
tion in endogenous PPT1 activity based on theMU-6S-Palm-bD-
Glc substrate assay (Figure 4D).ª2015 Elsevier Ltd All rights reserved 933
Table 1. IC50 Values for Inhibition of Human PPT1 by
Representative NHHCarbamatesMeasured in PPT1-Transfected
Cells or Cell Lysates
NHH Carbamate In Situ (ABPP)a In Vitro (Substrate)b
ABC44 (17) 0.1 (0.04–0.2) 6.5 (3.6–12)
ABC51 (14) 3.9 (2.0–7.4) >50
JJH254 (7) 0.5 (0.3–1.0) 15 (9.5–25)
IC50 values are in mM with 95% confidence intervals in parentheses.
aPPT1-transfected cells in situ, competitive ABPP.
bCell lysates in vitro, pH 5.0, MU-6S-Palm-bD-Glc substrate.A second compound of interest was ABC51 (14), which
showed limited activity against PPT1 in situ (Figures 4A and
4D; Table 1) or in vitro (Figure 4B and Table 1), but was a good
inhibitor of ABHD4 in vitro (IC50 value of 0.5 mM) as measured
with an N-acyl phosphatidylethanolamine (NAPE) substrate hy-
drolysis assay performed with lysates from ABHD4-transfected
HEK293T cells (Figure S4B). In contrast, neither ABC44 (17)
nor the LYPLA1/2 inhibitor JJH254 (7) altered the NAPE hydroly-
sis activity of ABHD4 (Figure S4B). JJH254 did, however, inhibit
PPT1 activity both in vitro (Figure 4C and Table 1) and in situ (Fig-
ure 4A, Table 1, and Figure S4A), albeit with lower potency than
ABC44.
To evaluate the broader selectivity of ABC44 (17) and ABC51
(14) across the SH class, we treated heavy- and light-isotopically
labeled PC3 cells with inhibitor (ABC51 [1 mM]; or ABC44 [1 or
0.1 mM]; 4 hr) and DMSO, respectively, followed by ABPP-SILAC
analysis with either the FP-biotin or ABC45 probes. ABC44 (17),
tested at 1 or 0.1 mM, near-completely inhibited PPT1 (90%+;
as measured by ABC45) and showed good selectivity, only
cross-reacting with two of the >40 quantified SH activities:
ABHD6 and CPVL (Figures 4E and S4C; Table S1). Conversely,
ABC51 (14) inhibited >90% of ABHD4 activity, as measured
with either the FP-biotin or ABC45 probes, and cross-reacted
with four additional targets: ABHD6, PAFAH2, PLA2G7, and
PLA2G15 (Figure 4C). We were initially surprised that ABC44
(17), when tested at 0.1 mM, produced near-complete blockade
of endogenous PPT1 in ABPP-SILAC experiments, given that
this concentration equals the in situ IC50 value of the inhibitor
measured with recombinant PPT1 (see Table 1 and Figure S4A).
We speculate that the potency of ABC44 (17) may be blunted in
transfected cells due to the higher cellular concentration of PPT1
compared with the endogenous levels of this enzyme found in
other cells. Finally, even when tested at concentrations substan-
tially above those required to inhibit their primary targets, ABC44
(17) and ABC51 (14) did not cause cytotoxicity (cell toxicity IC50
values >50 mM).
These results demonstrate that ABC44 (17) andABC51 (14) are
cell-active inhibitors that display good potency and selectivity for
PPT1 and ABHD4, respectively. While we do not yet understand
the basis for the markedly enhanced potency displayed by
ABC44 (and JJH254 [7]) for PPT1 in situ versus in vitro, it is
possible that these compounds preferentially accumulate in the
lysosomal compartment of cells to promote PPT1 inactivation.
In Vivo Activity of NHH Carbamates
We next asked whether representative NHH carbamates could
inhibit their SH targets in vivo. ABC44 (17), ABC51 (14), and934 Chemistry & Biology 22, 928–937, July 23, 2015 ª2015 Elsevier LJJH254 (7) were administered across a dose range of
1–40 mg/kg to C57Bl/6 mice by intraperitoneal injection, and,
after 4 hr, animals were euthanized and tissues harvested for
analysis by gel-based ABPP using the FP-Rh and ABC45
probes. ABC44 (17) showed potent, dose-dependent inhibition
of an ABC45-reactive protein matching the molecular mass of
deglycosylated PPT1 in PNGaseF-treated central and peripheral
tissues, producing near-complete blockade of this enzyme ac-
tivity at 1–5 mg/kg (Figures 5A and S5A). ABC44 (17) showed
excellent selectivity for PPT1, and did not inhibit other SHs de-
tected in brain and testis tissues treated with the FP-Rh (Fig-
ure S5A) or ABC45 (Figures 5A and S5A) probes. JJH254 (7)
also showed good in vivo activity, producing near-complete
blockade of LYPLA1 and LYPLA2 in peripheral (e.g., liver, kid-
ney), but not central (brain) tissues at a dose of 5 mg/kg as
measured with the FP-Rh probe (Figures 5B and S5A). JJH254
(7) also showed limited cross-reactivity with other SHs, consis-
tent with competitive ABPP-SILAC studies in human cells (Fig-
ure S5B and Hulce et al., 2014), but did inhibit PPT1 at doses
of 10 mg/kg or greater as measured with ABC45 (Probe 1) (Fig-
ure 5B). Contrasting with these results, ABC51 (14) did not block
the activity of ABHD4 in any tissue examined (data not shown),
possibly indicating that improvements in potency and/or drug-
like properties are required to convert this compound into an
in vivo-active probe.
DISCUSSION
In the present work, we have examined an underexplored class
of carbamate inhibitors bearing extended NHH LGs against
the SH enzyme class using competitive ABPP. NHH carbamates
inhibited SHs that have proven largely insensitive to other
carbamate scaffolds, including ABHD3, ABHD4, and PPT1.
That PPT1 is also poorly reactive with FPs (Martin et al., 2012;
Wang et al., 2013), which represent arguably the most generic
SH-directed electrophile, underscores the remarkable selec-
tivity individual SHs can display for specific reactive chemo-
types. Such restricted reactivity relationships, when uncovered,
can form the basis for the design of selective inhibitors and
tailored ABPP probes, as we have shown herein for PPT1 and
ABHD4.
Our most advanced PPT1 inhibitor, ABC44 (17), contains an
NHH LG that is nearly isosteric with that of ABC34 (13), but fea-
tures two trialkylated basic amines. This dibasic property could
contribute to the enhanced potency of ABC44 in cells compared
with cell lysates, since positively charged amine molecules have
been shown to accumulate in the lysosome (Goldman et al.,
2009), the subcellular compartment where PPT1 resides. How-
ever, the explanation for enhanced in situ potency of NHH carba-
mates for PPT1 is likely more complex, as JJH254 (7), which
lacks basic nitrogens, was also much more active against
PPT1 in cells. It is possible that other features shared between
ABC44 and JJH254 promote their accumulation in the lysosome
to facilitate PPT1 inhibition. That several other lysosomal hydro-
lases were unaffected by ABC44 (17), including CTSA, PRCP,
SCPEP1, and PPT2, indicates, regardless of mechanism, the
increased potency displayed by this NHH carbamate for PPT1
in cells compared with lysates does not unduly compromise
selectivity. Conversely, ABC44 (17) inhibited ABHD6, which istd All rights reserved
Figure 5. NHH Carbamates Inhibit PPT1 and
Other SHs In Vivo
Gel-based competitive ABPP analysis of SH ac-
tivities in tissues frommice treated with ABC44 (17)
(A) or JJH254 (7) (B). The activities of ABHD4 and
PPT1 were visualized using the ABC45 probe in
tissue proteomes treated with PNGaseF (post-
ABC45 labeling), while the activities of LYPLA1 and
LYPLA2 were visualized using the FP-Rh probe.not considered a lysosomal protein, indicating that this NHH
carbamate can access additional compartments in the cell.
In recombinant expression systems, PPT1 exhibited a minor,
upper molecular weight (MW) form (Figures 3D and 3E) that
was less sensitive to ABC34 (13) (Figure 3D). We speculate that
this upper MW species could represent a transitional form of
PPT1 as the protein migrates from the ER to the lysosome and
undergoes maturation through post-translational modification.
Whether such inhibitor-resistant forms of PPT1 reflect an artifact
of overexpression or might also exist endogenously is not yet
clear, but our ABPP-SILAC studies, where >90%of PPT1 activity
was blocked by ABC44 (17) (0.1–1 mM) in PC3 cells (Figures 4D,
and 4E, and S4C), would argue thatmost, if not all of endogenous
PPT1 is sensitive to ABC44 inhibition. From a methodological
perspective, these data underscore the importance of technolo-
gies, such as competitive ABPP, that can determine target
engagement for inhibitors in living systems (Simon et al., 2013),
as this parametermaydiffer substantially from inhibitor potencies
measured in vitro due to compound and/or target localization,
or other parameters that affect protein function in cells.
Deleterious mutations that impair PPT1 expression cause a
rare, Mendelian distributed genetic disorder termed Batten’s
disease or INCL (Kyttala et al., 2006). Peptide-based reversible
inhibitors of PPT1 have been described (Dawson et al., 2010;
Meng et al., 1998) with the potential to serve as pharmacological
chaperones that could facilitate the transport of mutant PPT1
variants to the lysosome (Dawson et al., 2010), where improved
enzyme stability may be observed in the lower pH environment of
this organelle. Whether these peptide-based inhibitors can
affect PPT1 transport and/or function in vivo remains unclear.
Assuming that restoration of PPT1 activity (and not merelyChemistry & Biology 22, 928–937, July 23, 2015expression) is required to reverse the
pathophysiological phenotypes observed
in INCL, it is unlikely that NHH carba-
mates, being irreversible inhibitors, would
offer a potential treatment strategy for
this disease. We believe, however, that
ABC44 (17) and related NHH carbamates
should serve as useful probes to charac-
terize the function of PPT1 in cell and
animal models. These pharmacological
studies, which could also employ control
probes that inhibit some of the off-
targets of ABC44, but spare PPT1 activity,
e.g., ABHD6-selective inhibitors, such as
MJN193 described herein, and others
(Hsu et al., 2013; Janssen et al., 2014; Li
et al., 2007; Marrs et al., 2011), may illumi-nate the endogenous substrate, products, and pathways
affected by PPT1 inhibition and, through doing so, provide
mechanistic insights into the biochemical basis for INCL.
Finally, the NHH carbamates explored herein furnished lead
inhibitors for several additional SHs for which selective chemical
probes are currently lacking, including ABHD12, PLA2G15, and
CPVL (as well as the aforementioned ABHD3 and ABHD4). Aswe
have shown for ABHD3, ABHD4, and PPT1, each SH appears to
display a distinct SAR with the limited subset of NHH carba-
mates evaluated so far, suggesting that continued medicinal
chemistry exploration of this chemotype has the potential to
yield selective inhibitors for other SHs. We therefore conclude
that NHH carbamates represent a versatile scaffold for the dis-
covery and optimization of inhibitors for the pharmacological
characterization of SHs in living systems.
SIGNIFICANCE
This study explores NHH carbamates as inhibitors of the SH
enzyme class using ABPP methods. We show that NHH
carbamates offer advantages over previously described
classes of carbamate inhibitors of SHs, in particular by
permitting the facile derivatization of both SG and LG com-
ponents of the carbamate scaffold to improve inhibitor
potency and selectivity. We discover selective and in vivo-
active NHH carbamate inhibitors for SHs that heretofore
have lacked chemical probes, including PPT1, mutations of
which cause the neurological disease INCL. We further
show that these inhibitors can be converted into tailored
probes for profiling the activity and inhibition of PPT1
and other SHs in native biological systems. The selectiveª2015 Elsevier Ltd All rights reserved 935
inhibitors and activity probes described herein should facil-
itate the pharmacological analysis of PPT1 and other SHs in
cell and animal models and, through doing so, illuminate the
functions that these enzymes play in mammalian biology
and disease.
EXPERIMENTAL PROCEDURES
Gel-Based ABPP Analysis
Gel-based ABPP analysis was performed as described previously (Chang
et al., 2013). In brief, tissue and cell proteomes (1 mg/ml, 50 ml) were treated
with FP-Rh (1 mM, 30 min) or ABC45 (1 mM, 60 min) and chased with a rhoda-
mine-N3 tag under CuAAC conditions (Chang et al., 2013). Samples were then
quenched by adding 43 SDS-PAGE loading buffer (17 ml), resolved by SDS-
PAGE, and visualized using an FMBio II Multiview flatbed fluorescence
scanner (Hitachi) or a ChemiDocMP (Bio-Rad). Signal intensity was then quan-
tified with ImageJ 1.45s, and IC50 values were determined with GraphPad
Prism 5.01.
In Situ Inhibitor Treatment of Human Cell Lines
In situ inhibitor treatments of human cell lines were performed as described
previously (Hsu et al., 2012). In brief, PC3 or transfected HEK293T cells were
grown to confluency in media (RPMI or DMEM, respectively) supplemented
with serum. The culture medium was then removed and replaced with fresh
medium containing DMSO or inhibitors at the desired concentration, and incu-
bated for 4 hr in a tissue culture incubator (37C, 5% CO2). Cells were then
washed with PBS, harvested, washed with PBS once more, and lysed with a
probe sonicator in PBS.
In Vivo Administration of Inhibitors
Mice were injected with ABC44, ABC51, JJH254, or vehicle, as described pre-
viously (Chang et al., 2013; Hsu et al., 2012). In brief, C57Bl/6 mice were
injected intraperitoneally with an 18:1:1 (v/v/v) solution of saline/ethanol/
emulphor containing varying doses of compounds. After 4 hr, mice were anes-
thetized with isoflurane and euthanized by cervical dislocation, and harvested
tissues were prepared for gel-based ABPP analysis. The studies were per-
formed with the approval of the Institutional Animal Care and Use Committee
at The Scripps Research Institute in accordance with the Guide for the Care
and Use of Laboratory Animals.
ABPP-SILAC Sample Preparation and Data Analysis
ABPP-SILAC samples were prepared and analyzed as described previously
(Hsu et al., 2012). In brief, isotopically heavy and light PC3 cells (or cell lysates)
were treated with inhibitor or DMSO, respectively, and cell proteomes (500 ml,
2 mg/ml) were incubated with FP-biotin (2.5 mM, 1 hr) or ABC45 (5 mM, 1 hr) fol-
lowed by conjugation to biotin-N3 by CuAAC (Speers and Cravatt, 2004). Light
and heavy cell lysates were combined, additional PBS was added (1 ml), and
the resulting mixture was precipitated with 4:1 MeOH/CHCl3 (2.5 ml). Pellets
were then washed with 1:1 MeOH/CHCl3 (1 ml, 23 volume), resuspended in
0.5 ml of 6 M urea in PBS, reduced using tris(2-carboxyethyl)phosphine
(10 mM) for 30 min at 37C, and then alkylated using iodoacetamide (40 mM)
for 30 min at 25C in the dark. Biotinylated proteins were enriched with PBS-
washed streptavidin beads (100 ml, Sigma-Aldrich) by shaking at 25C for
1.5 hr in PBS (5.5 ml) with 2% SDS. The beads were washed sequentially
with 10 ml of PBS with 0.2% SDS (33), 10 ml of PBS (33), and 10 ml of DI
H2O (33). On-bead digestion was performed using sequence-grade trypsin
(2 mg; Promega) in 2 M urea in PBS with 2 mM CaCl2 for 12–14 hr at 37
C
(200 ml). Peptides obtained from this procedure were acidified using formic
acid (5% final) and stored at 20C before analysis. Digested peptides were
loaded on to a biphasic (strong cation exchange/reverse phase) capillary col-
umn and analyzed by 2D LC-MS/MS on an LTQ-Orbitrap (Thermo Scientific).
Samples were then searched using the ProLuCID algorithm against a human
reverse-concatenated non-redundant (gene-centric) FASTA database that
was assembled from the Uniprot database. SILAC ratios were quantified using
in-house CIMAGE software (Weerapana et al., 2010).
Additional Experimental Procedures can be found in Supplemental
Information.936 Chemistry & Biology 22, 928–937, July 23, 2015 ª2015 Elsevier LSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2015.05.018.
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